Vivos Inc Stock Performance
| RDGL Stock | USD 0.08 0 4.22% |
The entity has a beta of 1.31, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vivos will likely underperform. At this point, Vivos Inc has a negative expected return of -1.0%. Please make sure to validate Vivos' potential upside, daily balance of power, as well as the relationship between the Daily Balance Of Power and market facilitation index , to decide if Vivos Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Vivos Inc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
| Begin Period Cash Flow | 903.7 K |
Vivos |
Vivos Relative Risk vs. Return Landscape
If you would invest 16.00 in Vivos Inc on September 19, 2024 and sell it today you would lose (8.28) from holding Vivos Inc or give up 51.75% of portfolio value over 90 days. Vivos Inc is currently does not generate positive expected returns and assumes 5.1537% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of otc stocks are less volatile than Vivos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vivos Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vivos' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Vivos Inc, and traders can use it to determine the average amount a Vivos' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1939
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RDGL |
Estimated Market Risk
| 5.15 actual daily | 45 55% of assets are more volatile |
Expected Return
| -1.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vivos is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vivos by adding Vivos to a well-diversified portfolio.
Vivos Fundamentals Growth
Vivos OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Vivos, and Vivos fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vivos OTC Stock performance.
| Return On Equity | -1.17 | |||
| Return On Asset | -0.62 | |||
| Operating Margin | (67.68) % | |||
| Current Valuation | 15.27 M | |||
| Shares Outstanding | 359.89 M | |||
| Price To Earning | 0.17 X | |||
| Price To Book | 9.01 X | |||
| Price To Sales | 598.62 X | |||
| Revenue | 14.89 K | |||
| EBITDA | (2.5 M) | |||
| Cash And Equivalents | 1.99 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 295.76 K | |||
| Debt To Equity | 0.21 % | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (963.82 K) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 1.63 M | |||
About Vivos Performance
By examining Vivos' fundamental ratios, stakeholders can obtain critical insights into Vivos' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Vivos is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington. VIVOS INC operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 1 people.Things to note about Vivos Inc performance evaluation
Checking the ongoing alerts about Vivos for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Vivos Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vivos Inc generated a negative expected return over the last 90 days | |
| Vivos Inc has high historical volatility and very poor performance | |
| Vivos Inc has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 14.89 K. Net Loss for the year was (2.53 M) with profit before overhead, payroll, taxes, and interest of 2.89 K. | |
| Vivos Inc currently holds about 1.99 M in cash with (963.82 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
- Analyzing Vivos' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vivos' stock is overvalued or undervalued compared to its peers.
- Examining Vivos' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vivos' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vivos' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Vivos' otc stock. These opinions can provide insight into Vivos' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Vivos OTC Stock
Vivos financial ratios help investors to determine whether Vivos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vivos with respect to the benefits of owning Vivos security.